Detalhe da pesquisa
1.
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis.
Br J Haematol
; 189(5): 860-868, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068255
2.
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Br J Haematol
; 184(2): 232-241, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30203839
3.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Lancet Oncol
; 19(11): 1449-1458, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30348538
4.
Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
Br J Haematol
; 186(3): e7-e11, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30847896
5.
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
Adv Ther
; 38(1): 640-659, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33211297
6.
Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia.
J Clin Pharmacol
; 59(5): 668-676, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30536675
7.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
Clin Cancer Res
; 25(13): 3772-3775, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30890552